Transdrug doxorubicin regulatory update

FDA granted Orphan Drug designation to Transdrug doxorubicin to treat hepatocellular carcinoma (HCC). The nanoparticle formulation of doxorubicin, which is in a European Phase I/II trial, also has Orp...